Cardiovascular Toxicities of Novel Cancer Drugs

Join Dr Kathryn Ruddy (Mayo Clinic, US), Prof Dan Lenihan (Saint Francis Healthcare System, US), Prof Joe Carver (University of Pennsylvania, US), Dr Susan Dent (Duke University, US) and Melissa Chin (MASCC Executive Director) for an insightful broadcast that delves into the intricate interplay between novel cancer drugs and their potential impact on the cardiovascular system. As breakthroughs in oncology continue to unfold, understanding and managing associated cardiovascular toxicities become paramount.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits. 

This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

The Multinational Association of Supportive Care in Cancer (MASCC) is an international, interdisciplinary organisation dedicated to the practice, education and research of supportive care in cancer. MASCC mission is to continually improve the supportive care of people with cancer – from diagnosis through to survival or end-of-life care.

Support Statement

This is an independent activity run by the International Cardio-Oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. The IC-OS has been provided support to deliver this webinar series by AstraZeneca, BMS/Pfizer Alliance, Eli Lilly and Roche through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.